The seroepidemiology of Haemophilus influenzae type b prior to introduction of an immunization programme in Kathmandu, Nepal.
Haemophilus influenzae type b (Hib) is now recognized as an important pathogen in Asia. To evaluate disease susceptibility, and as a marker of Hib transmission before routine immunization was introduced in Kathmandu, 71 participants aged 7 months-77 years were recruited and 15 cord blood samples were collected for analysis of anti-polyribosylribitol phosphate antibody levels by enzyme-linked immunosorbent assay. Only 20% of children under 5 years old had levels considered protective (>0.15 µg/ml), rising to 83% of 15-54 year-olds. Prior to introduction of Hib vaccine in Kathmandu, the majority of young children were susceptible to disease.
Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Andrew S J
AS
Marshall
Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Charlotte I S
CI
Barker
Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Anoop S
AS
Pulickal
Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Elizabeth
E
Kibwana
Patan Hospital, Kathmandu, Nepal.
Samir C
SC
Gautam
Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Elizabeth A
EA
Clutterbuck
Patan Hospital, Kathmandu, Nepal.
Stephen M
SM
Thorson
Patan Hospital, Kathmandu, Nepal.
Shrijana
S
Shrestha
Patan Hospital, Kathmandu, Nepal.
Neelam
N
Adhikari
Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Andrew J
AJ
Pollard
Oxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Dominic F
DF
Kelly
D000293:Adolescent; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D016667:Bacterial Capsules / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D006192:Haemophilus Infections / Q000453:epidemiology / Q000276:immunology* / Q000382:microbiology; D018073:Haemophilus Vaccines / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000276:immunology* / Q000502:physiology; D054884:Host-Pathogen Interactions / Q000276:immunology; D006801:Humans; D017589:Immunization Programs / Q000379:methods*; D007223:Infant; D008875:Middle Aged; D009390:Nepal / Q000453:epidemiology; D011134:Polysaccharides / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D016036:Seroepidemiologic Studies; D014611:Vaccination / Q000379:methods; D055815:Young Adult
D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011134:Polysaccharides; D011135:Polysaccharides, Bacterial; C008984:polyribitol phosphate